4DMT to Host Investor Day on October 21, 2026
Key Highlights
- ➤4DMT to host Investor Day in New York City on October 21, 2026
- ➤4D-150’s wet AMD and diabetic macular edema indications are in Phase 3 development
- ➤4D-150 is designed for multi-year anti-VEGF delivery through a single intravitreal injection
* Company to share insights on the advancing clinical profile and commercial vision for 4D-150 * Renowned retinal experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Carl C. Awh, MD, FASRS; Dr. David Eichenbaum, MD, FASRS; and Dr. Sara J. Haug, MD, PhD, will join 4DMT leadership to offer perspective on transforming the treatment paradigm in VEGF-driven retinal diseases * Live event will take place in New York City on October 21, 2026 at 10:30am ET EMERYVILLE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the Company will host an Investor Day on Wednesday, October 21, 2026, in New York City. The live event will begin at 10:30am ET and include a Company presentation, KOL panel discussions and a live Q&A session.
Get started
Create a free account to read the full story.